Latest news with #EksoBionicsHoldingsInc
Yahoo
06-05-2025
- Business
- Yahoo
Ekso Bionics Holdings Inc (EKSO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...
Release Date: May 05, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Ekso Bionics Holdings Inc (NASDAQ:EKSO) reported a gross margin increase to 54% in Q1 2025, up from 52% in the same period of 2024, driven by cost savings in supply chain and reduced service costs. The company has successfully engaged Pre-Healthcare to enhance market access services, which has been instrumental in the commercialization of over 300 medical devices. Ekso Bionics Holdings Inc (NASDAQ:EKSO) has developed a pipeline of more than 35 Medicare beneficiaries as potential candidates for their exo Indigo Personal device, marking a 37% increase from the previous quarter. The company has strengthened its distribution network by partnering with National Seating and Mobility and Bionic P&O, which is expected to broaden access to their exoskeleton devices across the United States. Ekso Bionics Holdings Inc (NASDAQ:EKSO) reported an increase in cash and restricted cash to $8.1 million as of March 31, 2025, up from $6.5 million at the end of 2024, indicating improved financial stability. Revenue for Q1 2025 decreased to $3.4 million from $3.8 million in the same period of 2024, primarily due to capital budget impacts on inpatient rehabilitation facilities. The company reported a net loss of $2.9 million for Q1 2025, although this was an improvement from a $3.4 million loss in Q1 2024. There is uncertainty regarding the capital budgets of inpatient rehabilitation facilities, which could impact future sales of Ekso Bionics Holdings Inc (NASDAQ:EKSO)'s enterprise health products. The company faces challenges in ensuring successful Medicare claim submissions due to the lack of a definitive set of criteria published by CMS or DME MACs. Ekso Bionics Holdings Inc (NASDAQ:EKSO) anticipates potential longer-term impacts on capital budgets due to economic uncertainties, which could affect their enterprise health business. Warning! GuruFocus has detected 2 Warning Signs with EKSO. Q: How should investors think about the distribution of patients across different channels for the Indigo Personal product this year? A: Unidentified_6 explained that while the majority of their business has historically come from the enterprise health product portfolio, they expect enterprise products to represent 75% to 80% of their business in 2025. The personal product segment is expected to contribute significantly as they scale up market access capabilities. The distribution between CRT and ONP spaces is uncertain, but there is familiarity in the ONP space, and they expect contributions from both channels as the year progresses. Q: Can you provide more details on the progress with Pre-Healthcare and the claims submission process? A: Unidentified_6 stated that they have learned from past claims and have a strong understanding of what constitutes a successful claim. Although there is no definitive set of criteria published by CMS or DME MACs, their engagement with Pre-Healthcare has helped them submit comprehensive claims with a high probability of success. Q: What is the outlook for capital budgets in the enterprise segment, considering current economic uncertainties? A: Unidentified_6 mentioned that while they have a strong pipeline in the enterprise business, they are seeing temporary impacts on budgets due to economic uncertainties. They expect a solid contribution from IDNs in 2025, but there is some softness in capital budgets, particularly for independent hospitals and facilities relying on federal grants. Q: Is the current gross margin of over 53% sustainable, and can it improve as revenues expand? A: Unidentified_6 believes that the operations team has done an excellent job in keeping costs down, and they expect margins to improve as volumes increase. The lower volume of products in Q1 impacted margins, but they anticipate higher margins as they scale up. Q: How do the partnerships with National Seating & Mobility (NSM) and Bionic P&O enhance Ekso Bionics' market presence? A: Unidentified_6 explained that these partnerships enhance their value by leveraging the expertise of these organizations in processing claims and working with patients and payers. NSM's national coverage and Bionic P&O's presence in 12 states align well with Ekso Bionics' pipeline, facilitating better submissions and expanding reach. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data
San Francisco Chronicle
05-05-2025
- Business
- San Francisco Chronicle
Ekso Bionics: Q1 Earnings Snapshot
SAN RAFAEL, Calif. (AP) — SAN RAFAEL, Calif. (AP) — Ekso Bionics Holdings Inc. (EKSO) on Monday reported a loss of $2.9 million in its first quarter. The San Rafael, California-based company said it had a loss of 12 cents per share. The robotic exoskeleton company posted revenue of $3.4 million in the period. _____
Yahoo
04-03-2025
- Business
- Yahoo
Ekso Bionics Holdings Inc (EKSO) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...
Release Date: March 03, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Ekso Bionics Holdings Inc (NASDAQ:EKSO) achieved record revenue of $5.1 million in Q4 2024, marking a 5% increase from the same period in 2023. Gross profit for Q4 2024 was $2.7 million, with a gross margin of approximately 53%, up from 49% in Q4 2023, due to cost savings in supply chain and service costs. Operating expenses decreased by 15% in Q4 2024 compared to Q4 2023, attributed to a reduction in headcount and discretionary payroll costs. The company has engaged Priya Healthcare to assist with reimbursement services, which is expected to enhance market access and accelerate revenue growth in 2025. Ekso Bionics Holdings Inc (NASDAQ:EKSO) has established a strategic partnership with National Seating and Mobility to expand distribution of the Indigo personal device in the complex rehabilitation technology industry. Revenue for the full year 2024 was $17.9 million, a slight decline from $18.3 million in 2023, attributed to the absence of procurement cycles with large delivery networks. Net loss for Q4 2024 was $3.4 million, slightly higher than the $3.2 million loss in Q4 2023. The company faced challenges in submitting Medicare claims, with only one claim reimbursed by July 2024 and subsequent claims still in the appeals process. Ekso Bionics Holdings Inc (NASDAQ:EKSO) anticipates that the go-to-market program for the Indigo personal device will take time to scale and produce results. The company is still in the early stages of engaging with private insurance payers, focusing primarily on Medicare beneficiaries for the time being. Warning! GuruFocus has detected 2 Warning Signs with EKSO. Q: Can you discuss your confidence in securing multi-unit orders this year and the volume of claims you plan to submit? A: We expect to secure more multi-unit orders in 2025, particularly from larger health delivery networks as we return to their procurement cycles. Regarding CMS claims, we have a pipeline of about 25 individuals with suitable claims and anticipate growth in submissions throughout the year, which should positively impact our top line. Scott Davis, CEO Q: Can you provide additional color on the growth trajectory in Europe and the APAC regions for 2025 and beyond? A: In APAC, we expect continued growth with our XONR and Indigo therapy devices, and potential growth in the Indigo personal product line due to existing reimbursement programs. In Europe, we experienced exceptional growth in 2024, particularly in French hospital systems, and expect to return to normal growth levels in 2025. Scott Davis, CEO Q: How many individuals entering the queue for personal units are ultimately qualified for the technology? A: We prioritize individuals with Medicare coverage who meet the physical and health requirements for the technology. Currently, we have about 25 qualified individuals, but we are continually identifying more candidates as the program becomes more mainstream. Scott Davis, CEO Q: Is there a plan to engage private payers for reimbursement, and how does PRA Healthcare assist in this process? A: We are focusing on achieving consistent success with Medicare before engaging private payers. PRA Healthcare helps us navigate coding, coverage, and payment complexities, which will eventually aid in engaging private insurers. Scott Davis, CEO Q: Can you elaborate on the partnership with National Seating and Mobility and its significance in the CRT industry? A: Our partnership with National Seating and Mobility, a leader in the CRT industry, is crucial for expanding distribution of Indigo personal devices. They have expertise in handling complex reimbursement processes, which aligns with our strategy to work with top players in the industry. Scott Davis, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
